🇺🇸 FDA
Patent

US 11155803

Adenosine deaminase base editors and methods of using same to modify a nucleobase in a target sequence

granted A61PA61P43/00

Quick answer

US patent 11155803 (Adenosine deaminase base editors and methods of using same to modify a nucleobase in a target sequence) held by Beam Therapeutics Inc. expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Beam Therapeutics Inc.
Grant date
Tue Oct 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61P, A61P43/00